Poor Glycemic Control Is Associated With More Rapid Kidney Function Decline After the Onset of Diabetic Kidney Disease
- PMID: 38262002
- PMCID: PMC11244193
- DOI: 10.1210/clinem/dgae044
Poor Glycemic Control Is Associated With More Rapid Kidney Function Decline After the Onset of Diabetic Kidney Disease
Abstract
Background: The role of glycemic control and its variability on the rate of kidney function decline after the onset of diabetic kidney disease (DKD) remains unclear.
Methods: The association between baseline glycated hemoglobin (HbA1c) and rates of estimated glomerular filtration rate (eGFR) loss during follow-up was examined by mixed-effects linear regression in 530 individuals with type 1 diabetes and early-to-moderate DKD from the Preventing Early Renal Loss (PERL) trial and 2378 individuals with type 2 diabetes and established DKD from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The benefit of intensive vs standard glycemic control in slowing eGFR decline was examined in ACCORD. The associations between continuous glucose monitoring-derived short-term glycemic variability indices and rate of eGFR decline were also evaluated in PERL.
Results: A higher baseline HbA1c was associated with a more negative eGFR slope in both PERL and ACCORD (-0.87 and -0.27 mL/min/1.73 m2/year per Hba1c unit increment, P < .0001 and P = .0002, respectively). In both studies, the strength of this association progressively increased with increasing levels of albuminuria (P for interaction <.05). Consistent with this, the benefit of intensive glycemic control on eGFR decline was greater in ACCORD participants with severe rather than moderate albuminuria (+1.13 vs + 0.26 mL/min/1.73 m2/year, P = .01). No independent associations were found in PERL between short-term glycemic variability indices and rate of eGFR decline.
Conclusion: In both type 1 and type 2 diabetes, poor glycemic control is associated with a more rapid rate of glomerular filtration rate decline after DKD onset, especially in persons with severe albuminuria.
Keywords: diabetic kidney disease; glycemic control; kidney function decline.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures


Similar articles
-
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.Diabetes Care. 2019 Aug;42(8):1454-1463. doi: 10.2337/dc19-0342. Epub 2019 Jun 11. Diabetes Care. 2019. PMID: 31186299 Free PMC article. Clinical Trial.
-
Annual deterioration of renal function in hypertensive patients with and without diabetes.Vasc Health Risk Manag. 2017 Jun 26;13:231-237. doi: 10.2147/VHRM.S135253. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28721063 Free PMC article.
-
Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.J Nephrol. 2001 Nov-Dec;14(6):461-71. J Nephrol. 2001. PMID: 11783602 Clinical Trial.
-
Diabetic Kidney Disease: Is There a Role for Glycemic Variability?Curr Diab Rep. 2018 Feb 15;18(3):13. doi: 10.1007/s11892-018-0979-3. Curr Diab Rep. 2018. PMID: 29450720 Review.
-
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1127-1150. doi: 10.1016/j.numecd.2019.07.017. Epub 2019 Oct 2. Nutr Metab Cardiovasc Dis. 2019. PMID: 31586514 Review.
Cited by
-
Good metabolic control is associated with decreased circulating factor VIIa- antithrombin complexes in type 2 diabetes: a cross-sectional study.Cardiovasc Diabetol. 2024 Nov 5;23(1):398. doi: 10.1186/s12933-024-02480-z. Cardiovasc Diabetol. 2024. PMID: 39501309 Free PMC article.
-
Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review.Int J Mol Sci. 2025 Apr 22;26(9):3935. doi: 10.3390/ijms26093935. Int J Mol Sci. 2025. PMID: 40362176 Free PMC article.
-
Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence.J Endocrinol Invest. 2025 Aug;48(8):1759-1768. doi: 10.1007/s40618-025-02602-8. Epub 2025 May 10. J Endocrinol Invest. 2025. PMID: 40347422 Free PMC article.
-
Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy.Front Immunol. 2025 Jun 4;16:1587806. doi: 10.3389/fimmu.2025.1587806. eCollection 2025. Front Immunol. 2025. PMID: 40534883 Free PMC article. Review.
-
Glycemic index of some protein-free food products for individuals with non-dialysis-dependent chronic kidney disease.Nutr Metab (Lond). 2025 Aug 6;22(1):93. doi: 10.1186/s12986-025-00990-5. Nutr Metab (Lond). 2025. PMID: 40770657 Free PMC article.
References
-
- United States Renal Data System . 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. 2022. https://adr.usrds.org/2022 - PMC - PubMed
-
- Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol. 2014;2(11):867‐874. - PubMed
-
- Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47(6):1703‐1720. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- General Clinical Research Centers and Clinical and Translational Science Awards
- UL1-TR-002494/TR/NCATS NIH HHS/United States
- Washington University DRC
- 17-2012-377/JDRF/United States
- P30 AG024824/AG/NIA NIH HHS/United States
- 2018PG-TlD014/Helmsley Charitable Trust
- N01-HC-95178/HL/NHLBI NIH HHS/United States
- P30 DK020572/DK/NIDDK NIH HHS/United States
- #NNF OC0013659/Novo Nordisk Foundation
- R01-DK-126373/NH/NIH HHS/United States
- CC/CDC HHS/United States
- Y01 HC001010/HC/NHLBI NIH HHS/United States
- UL1 TR001105/TR/NCATS NIH HHS/United States
- EY/NEI NIH HHS/United States
- P30-AG-024824/AG/NIA NIH HHS/United States
- R03-DK-094484/DK/NIDDK NIH HHS/United States
- P30 DK036836/DK/NIDDK NIH HHS/United States
- R01 DK126373/DK/NIDDK NIH HHS/United States
- P30 DK020579/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous